000			01993 a2200565 4500
005			20250513065952.0
264		0	_c19931228
008			199312s 0 0 eng d
022			_a0022-1899
024	7		_a10.1093/infdis/168.6.1387 _2doi
040			_aNLM _beng _cNLM
100	1		_aBelshe, R B
245	0	0	_aSafety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. _h[electronic resource]
260			_bThe Journal of infectious diseases _cDec 1993
300			_a1387-95 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAIDS Vaccines _xadministration & dosage
650	0	4	_aAdjuvants, Immunologic
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnimals
650	0	4	_aAntibodies, Antinuclear _ximmunology
650	0	4	_aCells, Cultured
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aGene Products, env _xadverse effects
650	0	4	_aGlycosylation
650	0	4	_aHIV Envelope Protein gp160
650	0	4	_aHIV-1 _ximmunology
650	0	4	_aHumans
650	0	4	_aLymphocytes _ximmunology
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProtein Precursors _xadverse effects
650	0	4	_aSafety
650	0	4	_aVaccines, Synthetic _xadministration & dosage
650	0	4	_aVero Cells
700	1		_aClements, M L
700	1		_aDolin, R
700	1		_aGraham, B S
700	1		_aMcElrath, J
700	1		_aGorse, G J
700	1		_aSchwartz, D
700	1		_aKeefer, M C
700	1		_aWright, P
700	1		_aCorey, L
773	0		_tThe Journal of infectious diseases _gvol. 168 _gno. 6 _gp. 1387-95
856	4	0	_uhttps://doi.org/10.1093/infdis/168.6.1387 _zAvailable from publisher's website
999			_c8244805 _d8244805